Publications

Filter Publications By:

Filanesib / Multiple Myeloma

06/04/2012

Cambridge Healthtech Institute Conference

The Discovery and Optimization of Kinesin Spindle Protein (KSP) Inhibitors: Path to ARRY-520

S. Allen, et al.

Binimetinib / Cancer

06/04/2012

American Society of Clinical Oncology Annual Meeting

Efficacy and Safety of Oral MEK162 in Patients with Locally Advanced and Unresectable or Metastatic Cutaneousmelanoma Harboring BRAFV600 or NRAS Mutations

P. A. Ascierto, et al.

Ipatasertib / Cancer

06/04/2012

American Society of Clinical Oncology Annual Meeting

A Phase Ib/II Study Testing the Safety and Efficacy of Combined Inhibition of the PI3K/Akt and Androgen Receptor Signaling Pathways in Castration-resistant Prostate Cancer: GDC-0068 or GDC-0980 with Abiraterone Acetate Versus Abiraterone Acetate

R. Funke, et al.

Selumetinib / Cancer

06/04/2012

American Society of Clinical Oncology Annual Meeting

Reacquisition of RAI incorporation of RAI]refractory metastatic thyroid cancers by pretreatment with the selective MEK inhibitor Selumetinib (AZD6244): A pilot study (NCT00970359)

A. L. Ho, et al.

Ipatasertib / Cancer

06/02/2012

American Society of Clinical Oncology Annual Meeting

A Phase Ib Study of the Akt Inhibitor GDC-0068 with Docetaxel or mFOLFOX6 in Patients with Advanced Solid Tumors

C. Saura, et al.

Selumetinib / Cancer

04/02/2012

American Association for Cancer Research Annual Meeting

A PHASE II TRIAL OF SELUMETINIB (AZD6244; ARRY-142886)

J. Farley, et al.

Filanesib / Multiple Myeloma

04/02/2012

American Association for Cancer Research Annual Meeting

Human Tumor Explants are Better Predictors of Clinical Trial Outcome than Solid Tumor Cell Line Xenografts for the KSP Inhibitor ARRY-520

M. J. Humphries, et al.

ARRY-380 / Breast Cancer

04/01/2012

American Association for Cancer Research Annual Meeting

ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice

V. Dinkel, et al.

ARRY-614 / MDS

03/09/2012

International Congress on Targeted Anticancer Therapies

ARRY-614, a Dual p38/Tie2 Inhibitor for Myelodysplastic Syndromes: Overview of the Phase 1 Experience

S. L. Winski, et al.

Selumetinib / Cancer

01/29/2012

Anti-Cancer Drugs

A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244)

M. J. Boers-Sonderen